February 4,XtalPi(Stock Code:2228.HK) announced that it will partner with Mirxes (stock code: 2629.HK), a global leader in early gastric cancer screening, and Signet Therapeutics, an innovative drug research and development company, to jointly establish a precision prevention and treatment system for gastric cancer centered on AI, covering the entire process of "early screening-diagnosis-treatment."Advance the prevention and treatment of gastric cancer in China and Asia.Three companies willJointly establish a joint venture in China and SingaporeExpand the Asian Market. This project relies on XtalPi's AI + robotics drug discovery platform, Miread's world-leading early-stage gastric cancer screening technology, and SIGNET's world-first diffuse gastric cancer targeted drug pipeline.Expected to gradually build a full-cycle treatment closed-loop system for gastric cancer, covering "early screening, early diagnosis, and early treatment" within the next five years.，Comprehensively improve the penetration rate of early gastric cancer screening and the coverage of precise diagnosis and treatment, assist in gradually reducing the incidence and mortality of gastric cancer in Asia, significantly enhance the accessibility of early gastric cancer screening and the effectiveness of treatment in China and even Asia, and strive to systematically reduce the burden of gastric cancer on patients' families and the medical system in China before 2031. Gradually eliminate the major health threat of gastric cancer and jointly overcome the challenges of gastric cancer prevention and treatment with cutting-edge technologies. Current Status of Gastric Cancer Prevention and Treatment in China:Insufficient Early Screening and Lagging Treatment: Urgent Need for Technological Breakthrough
Gastric cancer has an extremely high incidence and mortality rate in the Asian region, consistently ranking among the leading causes of cancer-related deaths;Nearly half of global stomach cancer deaths occur in Asia, with a five-year survival rate for advanced patients less than 10% worldwide.. The number of gastric cancer cases and deaths in China remains high, and the majority of patients are diagnosed at an advanced stage, resulting in a significantly lower five-year survival rate compared to countries like Japan and South Korea where early screening is widely implemented. According to data released by the National Cancer Center in 2024,The annual number of new gastric cancer cases in China exceeds 350,000., ranking 5th among all malignant tumors;The death toll exceeds 260,000, ranking third among malignant tumors. Among them, Diffuse Gastric Cancer (DGC) accounts for about one-third of all gastric cancer cases. As a difficult-to-treat subtype, it still lacks effective treatment methods and is not very sensitive to approaches such as radiotherapy, chemotherapy, and immunotherapy, leaving clinical needs largely unmet.Dr. Shuhaotem Wen, Chairman of XtalPi, said"China's gastric cancer prevention and treatment face two core challenges — insufficient accessibility of early screening and the need to improve the efficiency of innovative drug development. XtalPi, in collaboration with industry partners, is committed to overcoming these challenges in gastric cancer prevention and treatment. We aim to deeply empower the entire chain of gastric cancer prevention and treatment through AI technology: on one hand, optimizing early screening techniques to ensure more patients are detected at a curable stage; on the other hand, accelerating the R&D of innovative drugs to provide precise treatment options for diagnosed patients. We firmly believe,The ultimate goal of technological innovation is to transform cutting-edge breakthroughs into accessible health benefits for the public.Allow every patient to enjoy a longer life and better living.。”![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]()
Strategic Investment in Miread:AI Empowers Globally Leading Early Screening Technology
As an important part of this plan, XtalPi participated in the new share placement of Mira as a strategic investor and reached an in-depth technical cooperation. The core product of Mira is "Mi Xiao Wei"It is the world's first approved blood-based early screening product for gastric cancer and has been approved for marketing in China.In 2025, XtalPi and MiRXES reached a strategic cooperation to jointly build an AI-powered "integration of diagnosis and treatment" innovative research and industrialization platform, working together to create an end-to-end solution from early detection to precise intervention and treatment. XtalPi will empower and accelerate MiRXES' early screening pipeline from two dimensions based on its industry-leading AI algorithms and quantum physics computing platform. On the one hand, the two companies will engage in in-depth cooperation,Algorithm Optimization for Early Screening Technology: Mirx has accumulated a wealth of genomic and blood multi-omics data from Asian populations.Through XtalPi's machine learning infrastructure, there is potential to further optimize the accuracy and generalization ability of MiRXES' early screening model, particularly in developing specific screening markers for high-incidence gastric cancer subtypes in China (such as Helicobacter pylori-associated types); on the other hand,Initiate Pipeline Conversion for Discovered Potential Therapeutic Targets: Explore differentiated molecular targets discovered in early screening, inversely empower the continuous development of SIGNET's innovative gastric cancer drug pipeline, and provide a real-world foundation for XtalPi's drug research efforts, forming a closed loop of "early screening guiding medication, medication validating early screening."Mirui CEO Dr. Lihan Zhou pointed out"In the era of AI-driven medical innovation, the integration of XtalPi's AI platform with MiRXes' multi-omics blood-based early screening technology allows for in-depth analysis of the 100,000-plus clinical and real-world data accumulated over the past 12 years across multiple Asia-Pacific countries. This can further enhance the accuracy and accessibility of existing single-cancer early screening, accelerate the development of multi-cancer early screening products by more than three times, and reduce costs, making early screening a part of universal healthcare. At the same time, MiRXes’ clinical experience can also help XtalPi discover more innovative targets and anti-cancer drugs with significant market value, enabling seamless integration of precise diagnosis and treatment of gastric cancer, further reducing mortality."![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() Breakthrough Achieved in the Development of the World's First Targeted Drug for Diffuse Gastric CancerOn the treatment front, SIGNET, incubated by XtalPi, has become a key pillar of the program.Jointly developed by the two companiesSIGX1094Is the world's first targeted drug for diffuse gastric cancer to enter clinical trialsThe drug, designed based on an innovative target, underwent precise optimization of efficacy, safety, and developability using AI and organoids, and has entered Phase I clinical trials. In 2025, due to its breakthrough potential, SIGX1094 was nominated for the "Nobel Prize of the pharmaceutical industry," the Prix Galien. Meanwhile, Signet Therapeutics was awarded the "Drug Discovery Innovation Award" by the Biotech Breakthrough Organizing Committee, signifying that its first-in-class drug pipeline, developed in collaboration with XtalPi, along with its "Organoid+AI" drug discovery platform, gained international authoritative recognition.SIGNET simultaneously possesses the world's leading gastric cancer organoid models, which can highly simulate the characteristics of Asian gastric cancer subtypes. Through in-depth collaboration, XtalPi and SIGNET combine Mirxes’ early screening biomarkers with SIGNET’s organoid drug sensitivity testing to achieve precise "screening-to-treatment" matching. Leveraging their deep scientific research accumulation in biology and organoid+AI platform capabilities, they establish models for the novel disease targets discovered by Mirxes, validate their developability, and advance these discoveries toward the R&D transformation of new drug pipelines.Dr. Haisheng Zhang, founder of SIGNET, stated:"The current treatment options for advanced gastric cancer, such as diffuse gastric cancer, are limited. The progress in the development of SIGX1094 brings new hope to patients with this type of cancer. Through collaboration with XtalPi and Miread, we will further optimize our drug development strategy. Leveraging SIGNET's unique organoid+AI platform and XtalPi’s AI+robotics drug discovery platform, we aim to advance the development of targeted oncology drugs with high market potential, working together with industry partners to help cancer patients overcome the dilemma of having ‘no available treatment’."![]() ![]() ![]() ![]() ![]() ![]() ![]() AI Empowers Tripartite Technical Collaboration,Building a New Paradigm for Gastric Cancer Prevention and TreatmentThis program not only holds significant social value but also demonstrates considerable commercial prospects. The global market for early cancer screening is in a rapid development phase, expected to reach 360 billion US dollars by 2033. Meanwhile, the global gastric cancer treatment market is projected to reach...With a scale of 7.05 billion US dollars, the Asia-Pacific region dominates the global market with a 39.38% share. The market is expected to reach 31.31 billion US dollars by 2034, with a compound annual growth rate of 18.23% during the period. With the rapid development of China's early cancer screening market and the continuous advancement of innovative drug research and development,The tripartite cooperation is expected to establish long-term competitive advantages and unique technical synergies in the field of gastric cancer prevention and treatment. Through the establishment of a joint venture between China and Singapore, they will jointly promote business expansion in the Asian market and share future commercialization benefits.XtalPi's AI platform will simultaneously optimize early screening technologies and enhance the efficiency of drug development. Mirxes' clinical experience will provide a real-world foundation for drug development, while SIGNET's innovative drug research will further expand treatment options for gastric cancer. This closed-loop model covering the entire "screening-diagnosis-treatment" chain is expected to bring revolutionary breakthroughs to gastric cancer prevention and treatment in China.
The establishment of this AI-powered early screening and precision diagnosis-treatment closed-loop system for gastric cancer represents the determination of Chinese innovative enterprises to tackle major diseases. The strong collaboration between XtalPi, MiRXES, and SIGNET continues to improve the industrial ecosystem’s closed loop, reshaping the landscape of gastric cancer prevention and treatment through technological innovation. This effort makes precise, efficient, and affordable cancer diagnosis and treatment services accessible to China and a broader Asian region, jointly addressing the significant threat posed by gastric cancer, safeguarding human health, and bringing tangible benefits to patients in China and across Asia.
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]()
● CloseYuMiread● MiraDx (Stock Code: 2629.HK) was founded in 2014 and is a biotechnology company originating from Singapore, focusing onmiRNA Detection TechnologyInnovation and Application in Early Cancer Screening. The core product of Miread, GASTROClear, is the world's first and only approved molecular early screening product for gastric cancer. It has completed prospective clinical validation involving over 15,000 participants and has been approved in Singapore, China, and the EU. It has also received the Breakthrough Device Designation from the US FDA. Miread’s clinical pipeline includes high-incidence cancers such as lung cancer, colorectal cancer, liver cancer, and breast cancer. Powered by dual engines in Singapore and China, Miread’s clinical operations cover major markets in Southeast Asia and East Asia. With the mission of "making early cancer diagnosis accessible to all," Miread collaborates with numerous top medical institutions and research organizations worldwide to transform multi-omics diagnostic technologies into affordable clinical tools, supporting the early detection and intervention of major diseases like cancer to improve human health outcomes.● CloseSIGNET ● SIGNET is a pioneer in the global "organoid + AI" drug research and development model. It is a specialized and innovative enterprise in Shenzhen and has been recognized as a national high-tech enterprise. The company was initially founded on the campus of Harvard University and officially established in Shenzhen by the end of 2020, having since completed nearly 220 million yuan in financing and project funding. Currently, the company has four drug pipelines, with the first pipeline developing SIGX1094, the world's first targeted drug for diffuse gastric cancer, which has successively obtained IND approval from the U.S. FDA and China's NMPA, and received recognition from the U.S. FDA.Orphan Drug DesignationAnd has been granted Fast Track designation, entering the Phase I clinical trial stage. | 
